NCT00412880 - BI 2536 Second Line Monotherapy in SCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 14, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Carcinoma, Small Cell

Interventions

DRUG

BI 2536

Intravenous Infusion

Trial Locations (10)

1216.11.007 Boehringer Ingelheim Investigational Site, Fayetteville

1216.11.003 Boehringer Ingelheim Investigational Site, Chicago

1216.11.006 Boehringer Ingelheim Investigational Site, Evanston

1216.11.002 Boehringer Ingelheim Investigational Site, Boston

1216.11.005 Boehringer Ingelheim Investigational Site, St Louis

1216.11.001 Boehringer Ingelheim Investigational Site, Chapel Hill

1216.11.011 Boehringer Ingelheim Investigational Site, Charleston

1216.11.010 Boehringer Ingelheim Investigational Site, Greenville

1216.11.012 Boehringer Ingelheim Investigational Site, Seattle

1216.11.009 Alberta Cancer Board, Edmonton